Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Deferred Taxes (2021 - 2025)

Ironwood Pharmaceuticals' Deferred Taxes history spans 5 years, with the latest figure at -$1.7 million for Q4 2025.

  • For Q4 2025, Deferred Taxes fell 104.25% year-over-year to -$1.7 million; the TTM value through Dec 2025 reached $40.8 million, down 40.08%, while the annual FY2025 figure was $40.8 million, 40.08% down from the prior year.
  • Deferred Taxes for Q4 2025 was -$1.7 million at Ironwood Pharmaceuticals, down from $27.8 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $41.1 million in Q4 2024 and bottomed at -$1.7 million in Q4 2025.
  • The 5-year median for Deferred Taxes is $14.2 million (2023), against an average of $14.0 million.
  • The largest annual shift saw Deferred Taxes skyrocketed 941.33% in 2022 before it tumbled 104.25% in 2025.
  • A 5-year view of Deferred Taxes shows it stood at $1.9 million in 2021, then surged by 941.33% to $20.1 million in 2022, then soared by 55.6% to $31.3 million in 2023, then soared by 31.23% to $41.1 million in 2024, then tumbled by 104.25% to -$1.7 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Deferred Taxes are -$1.7 million (Q4 2025), $27.8 million (Q3 2025), and $14.1 million (Q2 2025).